Product Code: BT 5504
The global biopsy device market is projected to reach USD 11.01 billion by 2030 from USD 7.27 billion in 2024, at a CAGR of 7.2% during the forecast period."
Scope of the Report |
Years Considered for the Study | 2024-2030 |
Base Year | 2023 |
Forecast Period | 2024-2030 |
Units Considered | Value (USD Billion) |
Segments | Product, Technology, Application, End User, and Region |
Regions covered | North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries |
One of the biggest drivers is the growing incidence of cancer, especially breast, lung, and prostate cancers, which need precise and early diagnostic tests. The World Health Organization states that cancer cases are likely to increase substantially by 2030. Therefore, there would be an increasing demand for biopsy devices. Also, the growing demand for less invasive procedures is driving market growth further. The newer biopsy methods like vacuum-assisted and liquid biopsies are more accurate, have lower recovery times, and cause lower patient discomfort Furthermore, advances in technology, such as robotic-assisted biopsy machines, AI-based diagnostic systems, and image-guided biopsy procedures, improve accuracy and efficiency, driving market growth further. Moreover, rising government programs for cancer screening, combined with rising healthcare spending, especially in developing nations, drive the market forward. Nonetheless, the high prices of sophisticated biopsy devices and strict regulatory environments can serve as constraints.
"The needle-based biopsy instrument segment to grow the fastest during the forecast period."
Based on the product, the biopsy device market is divided into Needle-based biopsy instrument, Visualization device, Brush biopsy instrument, Biopsy accessory and Robotic biopsy device. Among these, in 2023, Needle-based biopsy instrument segment account for the highest growing segment of 7.8% in biopsy device market. This is due to rising preference for the utilization of minimally invasive diagnostic interventions. The Needle biopsy devices such as core needle biopsy (CNB), fine needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB) devices provide a less painful and less invasive alternative to surgical biopsies. This lowers patient pain, recovery time, and procedural expenses. Moreover, the growing focus on early disease detection and precision medicine has also driven demand for needle biopsies, as they yield very accurate tissue samples with few complications. Further, the increasing trend towards ambulatory and outpatient facilities for biopsies has also increased the market, as needle biopsies are quick and require little infrastructure. However, the risks of bleeding, infection, and sampling errors pose challenges to the growth of this market.
"The gastroenterology segment accounts for the second largest market share in biopsy device market."
Based on application, the biopsy device market is segmented into oncology, Gastroenterology, Bone & Bone marrow biopsy and other applications. The gastroenterology segment accounts for the second largest market share in biopsy device market. This can be attributed to the growing cased of gastrointestinal (GI) diseases and technological advancements in endoscopic biopsy methods. Moreover, the GI disorders such as Colorectal cancer, gastric cancer, inflammatory bowel disease (IBD), celiac disease, and gastrointestinal infections need biopsy procedures for proper diagnosis. Further, the increasing incidence of colorectal cancer, one of the most recurrently diagnosed cancers globally, makes a major contribution to the need for GI biopsy devices. Furthermore, the growing use of image-guided biopsy methods, namely endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and fine-needle biopsy (EUS-FNB), improves diagnostic accuracy in deep-seated GI tumors, contributing to market growth. Moreover, rise in geriatric population suffering from GI disorders and advancements in healthcare infrastructure on a worldwide level favour market growth.
"Asia Pacific accounted for the fastest growing of the biopsy device market by region."
The global biopsy device market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is the fastest growing regional market for the biopsy device and is estimated to grow at the highest CAGR during the forecast period. The increasing incidence of cancer, coupled by demographic changes and lifestyle factors, has increased the need for early diagnosis, driving the use of biopsy procedures. Development of healthcare infrastructure, especially in nations such as China, India, and Japan, has increased access to sophisticated diagnostic technologies. Further, government initiatives and rising healthcare expenditures have also aided cancer screening programs, stimulating market growth. Moreover, the growing medical tourism industry in the region, specifically in countries with low-cost yet high-quality biopsy services, has also increased the growth in demand.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1-45%, Tier 2-30%, and Tier 3- 25%
- By Designation: C-level-35%, Director-level-25% and Others-40%
- By Region: North America-40%, Europe-20%, Asia Pacific-25%, Latin America- 10%, and Middle east and Africa-5%
Note 1: Note: Companies are classified into tiers based on their total revenue. As of 2023, Tier 1 = >USD 10.00 billion, Tier 2 = USD 1.00 billion to USD 10.00 billion, and Tier 3 = <USD 1.00 billion.
Note 2: C-level primaries include CEOs, CFOs, COOs, and VPs.
Note 3: Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers.
The major players operating in the biopsy device market are BD (US), Devicor medical products, Inc (US), Medtronic (Ireland), Cardinal Health (US), B.Braun SE ( Germany), Hologic,Inc (US), Olympus Corporation (Japan), Boston Scientific Corporation (US), FUJIFILM Corporation (Japan), Stryker (US), Teleflex Incorporated (US), CONMED Corporation (US), Merit Medical Systems (US), Johnson & Johnson Services,Inc. (US), Cook Group (US), MicroPort Scientific Corporation (China), Argon Medical Devices (US), INRAD, Inc (US), Summit Medical LLC (US), TransMed7, LLC (US), Dr. Japan Co., Ltd. (Japan), IZI Medical Products (US), Planmed Oy (Finland), Advin Health Care (India), Trivitron Healthcare (India).
Research Coverage
This report studies the biopsy device market based on product, type, technology, application end user and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.
This report provides insights on the following pointers:
- Analysis of Key divers (Rising prevalence of cancer), restraints (Increasing product recalls), Challenge (Technological advancements), opportunity (Underdeveloped healthcare infrastructure in emerging economies)
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the bbiopsy device market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the biopsy device market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the biopsy devices market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
TABLE OF CONTENTS
1 INTRODUCTION
- 1.1 STUDY OBJECTIVES
- 1.2 MARKET DEFINITION
- 1.3 STUDY SCOPE
- 1.3.1 MARKET SEGMENTATION & GEOGRAPHIC SPREAD
- 1.3.2 INCLUSIONS & EXCLUSIONS
- 1.4 YEARS CONSIDERED
- 1.5 CURRENCY CONSIDERED
- 1.6 STAKEHOLDERS
- 1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
- 2.1 RESEARCH DATA
- 2.1.1 SECONDARY DATA
- 2.1.1.1 Key data from secondary sources
- 2.1.2 PRIMARY DATA
- 2.1.2.1 Key data from primary sources
- 2.1.2.2 Key industry insights
- 2.2 MARKET SIZE ESTIMATION
- 2.3 ASSESSMENT OF MARKET SEGMENTS
- 2.4 ASSESSMENT OF GEOGRAPHIC SEGMENTS
- 2.5 MARKET BREAKDOWN & DATA TRIANGULATION
- 2.6 RESEARCH ASSUMPTIONS
- 2.7 RESEARCH LIMITATIONS
- 2.7.1 METHODOLOGY-RELATED LIMITATIONS
- 2.7.2 SCOPE-RELATED LIMITATIONS
- 2.8 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
- 4.1 OPPORTUNITIES FOR PLAYERS IN BIOPSY DEVICES MARKET
- 4.2 NORTH AMERICA: BIOPSY DEVICES MARKET, BY END USER
- 4.3 BIOPSY DEVICES MARKET: GEOGRAPHIC SNAPSHOT
- 4.4 BIOPSY DEVICES MARKET: GEOGRAPHIC MIX
- 4.5 BIOPSY DEVICES MARKET: DEVELOPING VS. DEVELOPED MARKETS, 2024 VS. 2030 (USD MILLION)
5 MARKET OVERVIEW
- 5.1 INTRODUCTION
- 5.2 MARKET DYNAMICS
- 5.2.1 DRIVERS
- 5.2.1.1 Rising prevalence of cancer
- 5.2.1.2 Increasing preference for minimally invasive surgeries
- 5.2.1.3 Initiatives undertaken by governments and global health organizations
- 5.2.1.4 Increased number of hospitals and diagnostic centers
- 5.2.1.5 Improved reimbursement policies
- 5.2.2 RESTRAINTS
- 5.2.2.1 Increasing product recalls
- 5.2.2.2 High risk of infections
- 5.2.3 OPPORTUNITIES
- 5.2.3.1 Technological advancements
- 5.2.3.2 Growing investments in emerging economies
- 5.2.4 CHALLENGES
- 5.2.4.1 Underdeveloped healthcare infrastructure in emerging economies
- 5.3 INDUSTRY TRENDS
- 5.3.1 MINIMALLY INVASIVE PROCEDURES
- 5.3.2 ROBOTIC-ASSISTED BIOPSY DEVICES
- 5.3.3 LIQUID BIOPSY TECHNOLOGY
- 5.4 TECHNOLOGY ANALYSIS
- 5.4.1 KEY TECHNOLOGIES
- 5.4.1.1 Robotic-assisted biopsy devices
- 5.4.1.2 Optical biopsy technologies
- 5.4.1.3 Minimally invasive biopsy devices
- 5.4.2 COMPLEMENTARY TECHNOLOGIES
- 5.4.2.1 Imaging technologies
- 5.4.2.2 Tissue analysis technologies
- 5.4.2.3 Artificial intelligence
- 5.4.3 ADJACENT TECHNOLOGIES
- 5.4.3.1 Digital pathology and AI integration
- 5.4.3.2 Precision medicine tools
- 5.4.3.3 Advanced needle and probe technologies
- 5.5 PORTER'S FIVE FORCES ANALYSIS
- 5.5.1 THREAT FROM NEW ENTRANTS
- 5.5.2 BARGAINING POWER OF SUPPLIERS
- 5.5.3 BARGAINING POWER OF BUYERS
- 5.5.4 THREAT FROM SUBSTITUTES
- 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
- 5.6 REGULATORY LANDSCAPE
- 5.6.1 REGULATIONS, BY REGION
- 5.6.1.1 North America
- 5.6.1.1.1 US
- 5.6.1.1.2 Canada
- 5.6.1.2 Europe
- 5.6.1.3 Asia Pacific
- 5.6.1.4 Latin America
- 5.6.1.5 Middle East & Africa
- 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
- 5.7 PATENT ANALYSIS
- 5.7.1 PATENT PUBLICATION TRENDS IN BIOPSY DEVICES MARKET
- 5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
- 5.8 TRADE ANALYSIS
- 5.9 PRICING ANALYSIS
- 5.9.1 AVERAGE SELLING PRICE OF KEY PLAYERS, BY KEY PRODUCT
- 5.9.2 AVERAGE SELLING PRICE TREND OF BIOPSY DEVICES, BY REGION
- 5.10 KEY CONFERENCES & EVENTS
- 5.11 KEY STAKEHOLDERS & BUYING CRITERIA
- 5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS
- 5.11.2 BUYING CRITERIA
- 5.12 BIOPSY DEVICES MARKET: UNMET NEEDS/EXPECTATIONS OF END USERS
- 5.13 ECOSYSTEM ANALYSIS
- 5.14 CASE STUDY ANALYSIS
- 5.14.1 CASE STUDY 1: DEVICELAB COLLABORATED WITH CLINICAL EXPERTS TO IDENTIFY LIMITATIONS OF EXISTING BREAST BIOPSY PROCEDURES
- 5.14.2 CASE STUDY 2: RESEARCHERS AT UNIVERSITY OF TWENTE DESIGNED ROBOTIC SETUP AND SOFTWARE ARCHITECTURE TO ASSIST RADIOLOGISTS IN TARGETING MRI-DETECTED SUSPICIOUS TUMORS
- 5.14.3 CASE STUDY 3: RESEARCH TEAM DESIGNED FLEXIBLE ROBOTIC SYSTEM FOR BIOPSY SAMPLING APPLIED TO HUMAN CORPSES PLACED INSIDE PROTECTIVE BODY BAGS
- 5.15 SUPPLY CHAIN ANALYSIS
- 5.16 ADJACENT MARKET ANALYSIS
- 5.16.1 BREAST BIOPSY DEVICES MARKET
- 5.17 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
- 5.18 INVESTMENT & FUNDING SCENARIO
- 5.19 IMPACT OF AI ON BIOPSY DEVICES MARKET
6 BIOPSY DEVICES MARKET, BY PRODUCT
- 6.1 INTRODUCTION
- 6.2 NEEDLE-BASED BIOPSY INSTRUMENT
- 6.2.1 CORE NEEDLE BIOPSY
- 6.2.1.1 Core needle biopsy device
- 6.2.1.1.1 Semi-automatic
- 6.2.1.1.1.1 Need for balance of user control and automated functionality in procedures to drive market
- 6.2.1.1.2 Automatic
- 6.2.1.1.2.1 Demand for efficiency and accuracy in biopsy procedures to boost growth
- 6.2.1.2 Core needle biopsy needle
- 6.2.1.2.1 Disposable
- 6.2.1.2.1.1 Need for infection control and safety concerns to boost growth
- 6.2.1.2.2 Reusable
- 6.2.1.2.2.1 Cost-effectiveness of reusable core biopsy needles to drive market
- 6.2.2 FINE NEEDLE ASPIRATION BIOPSY
- 6.2.2.1 Innovations in needle design, including thinner profiles and improved tip configurations, to drive market
- 6.2.3 VACUUM-ASSISTED BIOPSY
- 6.2.3.1 Increasing need for early and accurate cancer detection to drive market
- 6.3 VISUALIZATION DEVICE/SYSTEM
- 6.3.1 RISING PREVALENCE OF CANCER AND OTHER CHRONIC CONDITIONS TO DRIVE DEMAND FOR VISUALIZATION DEVICE
- 6.4 BRUSH BIOPSY INSTRUMENT
- 6.4.1 PREFERENCE FOR MINIMALLY INVASIVE BIOPSY PROCEDURES TO BOOST MARKET
- 6.5 BIOPSY ACCESSORY
- 6.5.1 BIOPSY FORECEP
- 6.5.1.1 General biopsy forcep
- 6.5.1.1.1 Demand for minimally invasive procedures and precise diagnostics to surge growth
- 6.5.1.2 Hot biopsy forecep
- 6.5.1.2.1 Unique ability of hot biopsy forecep to cut and coagulate tissue to support growth
- 6.5.2 TISSUE MARKER
- 6.5.2.1 Rising cases of breast cancer to boost market growth
- 6.5.3 LOCALIZATION WIRE
- 6.5.3.1 Ability of localization wire to detect precise target locations to drive growth
- 6.5.4 OTHER ACCESSORIES
- 6.6 ROBOTIC BIOPSY DEVICE
- 6.6.1 RAPID DEVELOPMENT OF ROBOTIC BIOPSY DEVICES TO BOOST GROWTH
7 BIOPSY DEVICES MARKET, BY TECHNOLOGY
- 7.1 INTRODUCTION
- 7.2 ULTRASOUND-GUIDED BIOPSY
- 7.2.1 ULTRASOUND GUIDANCE ENHANCES SAFETY, MINIMIZES COMPLICATIONS, AND IMPROVES DIAGNOSTIC ACCURACY
- 7.3 STEREOTACTIC-GUIDED BIOPSY
- 7.3.1 NEED FOR EFFICIENT AND ACCURATE BIOPSY PROCEDURES TO SUPPORT MARKET GROWTH
- 7.4 OTHER TECHNOLOGIES
8 BIOPSY DEVICES MARKET, BY APPLICATION
- 8.1 INTRODUCTION
- 8.2 ONCOLOGY
- 8.2.1 BREAST CANCER
- 8.2.1.1 Increasing demand for early and accurate diagnosis to boost growth
- 8.2.2 SOFT TISSUE CANCER
- 8.2.2.1 Advancements in diagnostics and growing emphasis on cancer therapeutics to drive market
- 8.3 GASTROENTEROLOGY
- 8.3.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES TO DRIVE MARKET
- 8.4 BONE & BONE MARROW BIOPSY
- 8.4.1 RISING EMPHASIS ON BONE MARROW BIOPSIES TO SUPPORT MARKET GROWTH
- 8.5 OTHER APPLICATIONS
9 BIOPSY DEVICES MARKET, BY END USER
- 9.1 INTRODUCTION
- 9.2 HOSPITALS & BREAST CARE CENTERS
- 9.2.1 DEMAND FOR STATE-OF-THE-ART BIOPSY FACILITIES TO DRIVE MARKET
- 9.3 DIAGNOSTIC IMAGING CENTERS
- 9.3.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO SUPPORT MARKET GROWTH
- 9.4 AMBULATORY SURGICAL CENTERS
- 9.4.1 GROWING FOCUS ON AMBULATORY CARE TO DRIVE MARKET
- 9.5 OTHER END USERS
10 BIOPSY DEVICES MARKET, BY REGION
- 10.1 INTRODUCTION
- 10.2 NORTH AMERICA
- 10.2.1 MACROECONOMIC OUTLOOK
- 10.2.2 US
- 10.2.2.1 Growth in elderly population to drive market
- 10.2.3 CANADA
- 10.2.3.1 Rising government investments to drive growth
- 10.3 EUROPE
- 10.3.1 MACROECONOMIC OUTLOOK
- 10.3.2 GERMANY
- 10.3.2.1 Increasing prevalence of chronic diseases to propel market
- 10.3.3 UK
- 10.3.3.1 Initiatives by government to support market growth
- 10.3.4 FRANCE
- 10.3.4.1 Rising number of diagnostic imaging centers to drive market
- 10.3.5 ITALY
- 10.3.5.1 Availability of reimbursement coverage to support market growth
- 10.3.6 SPAIN
- 10.3.6.1 Increasing focus on cancer research to propel market
- 10.3.7 REST OF EUROPE
- 10.4 ASIA PACIFIC
- 10.4.1 MACROECONOMIC OUTLOOK
- 10.4.2 CHINA
- 10.4.2.1 Rapidly growing geriatric population to propel market
- 10.4.3 JAPAN
- 10.4.3.1 High adoption of advanced technologies to support market growth
- 10.4.4 INDIA
- 10.4.4.1 Rising prevalence of chronic diseases to drive market
- 10.4.5 AUSTRALIA
- 10.4.5.1 Increasing investments in research to provide opportunities for market growth
- 10.4.6 SOUTH KOREA
- 10.4.6.1 Presence of well-developed healthcare systems to propel market
- 10.4.7 REST OF ASIA PACIFIC
- 10.5 LATIN AMERICA
- 10.5.1 MACROECONOMIC OUTLOOK
- 10.5.2 BRAZIL
- 10.5.2.1 Favourable demographic conditions to drive market
- 10.5.3 MEXICO
- 10.5.3.1 Increased medical tourism and better government healthcare initiatives to drive market
- 10.5.4 REST OF LATIN AMERICA
- 10.6 MIDDLE EAST & AFRICA
- 10.6.1 MACROECONOMIC OUTLOOK
- 10.6.2 GCC COUNTRIES
- 10.6.2.1 Expansion of healthcare providers to drive growth
- 10.6.3 REST OF MIDDLE EAST & AFRICA
11 COMPETITIVE LANDSCAPE
- 11.1 OVERVIEW
- 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
- 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BIOPSY DEVICES MARKET
- 11.3 REVENUE ANALYSIS
- 11.4 MARKET SHARE ANALYSIS
- 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
- 11.5.1 STARS
- 11.5.2 EMERGING LEADERS
- 11.5.3 PERVASIVE PLAYERS
- 11.5.4 PARTICIPANTS
- 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
- 11.5.5.1 Company footprint
- 11.5.5.2 Region footprint
- 11.5.5.3 Product footprint
- 11.5.5.4 Technology footprint
- 11.5.5.5 Application footprint
- 11.5.5.6 End user footprint
- 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
- 11.6.1 PROGRESSIVE COMPANIES
- 11.6.2 RESPONSIVE COMPANIES
- 11.6.3 DYNAMIC COMPANIES
- 11.6.4 STARTING BLOCKS
- 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
- 11.7 COMPANY VALUATION & FINANCIAL METRICS
- 11.7.1 COMPANY VALUATION
- 11.7.2 FINANCIAL METRICS
- 11.8 BRAND/PRODUCT COMPARISON
- 11.9 COMPETITIVE SCENARIO
- 11.9.1 PRODUCT LAUNCHES & APPROVALS
- 11.9.2 DEALS
- 11.9.3 EXPANSIONS
12 COMPANY PROFILES
- 12.1 KEY PLAYERS
- 12.1.1 BD (BECTON, DICKINSON AND COMPANY)
- 12.1.1.1 Business overview
- 12.1.1.2 Products offered
- 12.1.1.3 Recent developments
- 12.1.1.4 MnM view
- 12.1.1.4.1 Key strengths
- 12.1.1.4.2 Strategic choices
- 12.1.1.4.3 Weaknesses & competitive threats
- 12.1.2 DEVICOR MEDICAL PRODUCTS, INC
- 12.1.2.1 Business overview
- 12.1.2.2 Products offered
- 12.1.2.3 Recent developments
- 12.1.2.3.1 Product launches & approvals
- 12.1.2.4 MnM view
- 12.1.2.4.1 Key strengths
- 12.1.2.4.2 Strategic choices
- 12.1.2.4.3 Weaknesses & competitive threats
- 12.1.3 MEDTRONIC
- 12.1.3.1 Business overview
- 12.1.3.2 Products offered
- 12.1.3.3 MnM view
- 12.1.3.3.1 Key strengths
- 12.1.3.3.2 Strategic choices
- 12.1.3.3.3 Weaknesses & competitive threats
- 12.1.4 CARDINAL HEALTH
- 12.1.4.1 Business overview
- 12.1.4.2 Products offered
- 12.1.4.3 MnM view
- 12.1.4.3.1 Key strengths
- 12.1.4.3.2 Strategic choices
- 12.1.4.3.3 Weaknesses & competitive threats
- 12.1.5 HOLOGIC, INC.
- 12.1.5.1 Business overview
- 12.1.5.2 Products offered
- 12.1.5.3 Recent developments
- 12.1.5.3.1 Deals
- 12.1.5.3.2 Other developments
- 12.1.5.4 MnM view
- 12.1.5.4.1 Key strengths
- 12.1.5.4.2 Strategic choices
- 12.1.5.4.3 Weaknesses & competitive threats
- 12.1.6 B. BRAUN SE
- 12.1.6.1 Business overview
- 12.1.6.2 Products offered
- 12.1.7 OLYMPUS CORPORATION
- 12.1.7.1 Business overview
- 12.1.7.2 Products offered
- 12.1.7.3 Recent developments
- 12.1.8 BOSTON SCIENTIFIC CORPORATION
- 12.1.8.1 Business overview
- 12.1.8.2 Products offered
- 12.1.9 FUJIFILM CORPORATION
- 12.1.9.1 Business overview
- 12.1.9.2 Products offered
- 12.1.10 STRYKER
- 12.1.10.1 Business overview
- 12.1.10.2 Products offered
- 12.1.11 TELEFLEX INCORPORATED
- 12.1.11.1 Business overview
- 12.1.11.2 Products offered
- 12.1.12 CONMED CORPORATION
- 12.1.12.1 Business overview
- 12.1.12.2 Products offered
- 12.1.13 MERIT MEDICAL SYSTEMS
- 12.1.13.1 Business overview
- 12.1.13.2 Products offered
- 12.1.14 JOHNSON & JOHNSON SERVICES, INC.
- 12.1.14.1 Business overview
- 12.1.14.2 Products offered
- 12.1.15 COOK GROUP
- 12.1.15.1 Business overview
- 12.1.15.2 Products offered
- 12.1.15.3 Recent developments
- 12.1.15.3.1 Product launches & approvals
- 12.2 OTHER PLAYERS
- 12.2.1 MICROPORT SCIENTIFIC CORPORATION
- 12.2.2 ARGON MEDICAL DEVICES
- 12.2.3 INRAD, INC.
- 12.2.4 SUMMIT MEDICAL LLC
- 12.2.5 TRANSMED7, LLC
- 12.2.6 DR. JAPAN CO., LTD.
- 12.2.7 IZI MEDICAL PRODUCTS
- 12.2.8 PLANMED OY
- 12.2.9 ADVIN HEALTH CARE
- 12.2.10 TRIVITRON HEALTHCARE
13 APPENDIX
- 13.1 DISCUSSION GUIDE
- 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
- 13.3 CUSTOMIZATION OPTIONS
- 13.4 RELATED REPORTS
- 13.5 AUTHOR DETAILS